Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Express Scripts
Johnson and Johnson
Harvard Business School
Merck

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 8,315,810

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 8,315,810
Title:Apparatus, method, computer-readable medium, and use for therapy planning in treatment of a patient
Abstract: An apparatus, method, system, computer-readable medium and use for individual patient therapy planning of diseases such as cancer for different therapy modalities, such as radiation therapy and chemotherapy is provided. A new aspect of the invention is that the degree of bone marrow depression of the patient is related to the count of immature blood platelets, which are measured before each treatment. Some embodiments of the invention provide an advantage allowing reducing the level of uncertainty in the prediction of the risk of bone marrow depression, and thus enabling to safely improve the therapy effect by an increase of the radiation dosage and/or chemical dosage to the individual patient while the risk for bone marrow depression is minimized.
Inventor(s): Von Busch; Heinrich (Aachen, DE), Schweizer; Bernd (Herzogenrath, DE), Georgi; Jens Christoph (Aachen, DE)
Assignee: Koninklijke Philips Electronics N.V. (Eindhoven, NL)
Application Number:12/446,989
Patent Claims:see list of patent claims

Details for Patent 8,315,810

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Koninklijke Philips Electronics N.V. (Eindhoven, NL) 2026-11-10 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Koninklijke Philips Electronics N.V. (Eindhoven, NL) 2026-11-10 RX Orphan search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial Koninklijke Philips Electronics N.V. (Eindhoven, NL) 2026-11-10 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Baxter
Merck
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.